1
|
Purohit K, Reddy N, Sunna A. Exploring the Potential of Bioactive Peptides: From Natural Sources to Therapeutics. Int J Mol Sci 2024; 25:1391. [PMID: 38338676 PMCID: PMC10855437 DOI: 10.3390/ijms25031391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 01/18/2024] [Accepted: 01/21/2024] [Indexed: 02/12/2024] Open
Abstract
Bioactive peptides, specific protein fragments with positive health effects, are gaining traction in drug development for advantages like enhanced penetration, low toxicity, and rapid clearance. This comprehensive review navigates the intricate landscape of peptide science, covering discovery to functional characterization. Beginning with a peptidomic exploration of natural sources, the review emphasizes the search for novel peptides. Extraction approaches, including enzymatic hydrolysis, microbial fermentation, and specialized methods for disulfide-linked peptides, are extensively covered. Mass spectrometric analysis techniques for data acquisition and identification, such as liquid chromatography, capillary electrophoresis, untargeted peptide analysis, and bioinformatics, are thoroughly outlined. The exploration of peptide bioactivity incorporates various methodologies, from in vitro assays to in silico techniques, including advanced approaches like phage display and cell-based assays. The review also discusses the structure-activity relationship in the context of antimicrobial peptides (AMPs), ACE-inhibitory peptides (ACEs), and antioxidative peptides (AOPs). Concluding with key findings and future research directions, this interdisciplinary review serves as a comprehensive reference, offering a holistic understanding of peptides and their potential therapeutic applications.
Collapse
Affiliation(s)
- Kruttika Purohit
- School of Natural Sciences, Macquarie University, Sydney, NSW 2109, Australia;
- Australian Research Council Industrial Transformation Training Centre for Facilitated Advancement of Australia’s Bioactives (FAAB), Sydney, NSW 2109, Australia;
| | - Narsimha Reddy
- Australian Research Council Industrial Transformation Training Centre for Facilitated Advancement of Australia’s Bioactives (FAAB), Sydney, NSW 2109, Australia;
- School of Science, Parramatta Campus, Western Sydney University, Penrith, NSW 2751, Australia
| | - Anwar Sunna
- School of Natural Sciences, Macquarie University, Sydney, NSW 2109, Australia;
- Australian Research Council Industrial Transformation Training Centre for Facilitated Advancement of Australia’s Bioactives (FAAB), Sydney, NSW 2109, Australia;
- Biomolecular Discovery Research Centre, Macquarie University, Sydney, NSW 2109, Australia
| |
Collapse
|
2
|
Liu G, Bursill C, Cartland SP, Anwer AG, Parker LM, Zhang K, Feng S, He M, Inglis DW, Kavurma MM, Hutchinson MR, Goldys EM. A Nanoparticle-Based Affinity Sensor that Identifies and Selects Highly Cytokine-Secreting Cells. iScience 2019; 20:137-147. [PMID: 31569048 PMCID: PMC6833483 DOI: 10.1016/j.isci.2019.09.019] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Revised: 09/10/2019] [Accepted: 09/12/2019] [Indexed: 11/01/2022] Open
Abstract
We developed a universal method termed OnCELISA to detect cytokine secretion from individual cells by applying a capture technology on the cell membrane. OnCELISA uses fluorescent magnetic nanoparticles as assay reporters that enable detection on a single-cell level in microscopy and flow cytometry and fluorimetry in cell ensembles. This system is flexible and can be modified to detect different cytokines from a broad range of cytokine-secreting cells. Using OnCELISA we have been able to select and sort highly cytokine-secreting cells and identify cytokine-secreting expression profiles of different cell populations in vitro and ex vivo. We show that this system can be used for ultrasensitive monitoring of cytokines in the complex biological environment of atherosclerosis that contains multiple cell types. The ability to identify and select cell populations based on their cytokine expression characteristics is valuable in a host of applications that require the monitoring of disease progression.
Collapse
Affiliation(s)
- Guozhen Liu
- Graduate School of Biomedical Engineering, ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Faculty of Engineering, The University of New South Wales, Sydney, NSW 2052, Australia; ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia; International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan 430079, P. R. China.
| | - Christina Bursill
- Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5005, Australia; Heart Research Institute, Sydney 2042, Australia
| | - Siân P Cartland
- Heart Research Institute, Sydney 2042, Australia; Sydney Medical School, University of Sydney, Sydney, Australia
| | - Ayad G Anwer
- Graduate School of Biomedical Engineering, ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Faculty of Engineering, The University of New South Wales, Sydney, NSW 2052, Australia; ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia
| | - Lindsay M Parker
- ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia
| | - Kaixin Zhang
- ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia
| | - Shilun Feng
- ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia
| | - Meng He
- ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia
| | - David W Inglis
- ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia
| | - Mary M Kavurma
- Heart Research Institute, Sydney 2042, Australia; Sydney Medical School, University of Sydney, Sydney, Australia
| | - Mark R Hutchinson
- ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), School of Medicine, Adelaide University, Adelaide, SA 5005, Australia
| | - Ewa M Goldys
- Graduate School of Biomedical Engineering, ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Faculty of Engineering, The University of New South Wales, Sydney, NSW 2052, Australia; ARC Centre of Excellence in Nanoscale Biophotonics (CNBP), Macquarie University, Sydney, NSW 2109, Australia.
| |
Collapse
|
3
|
Fleury L, Faux C, Santos C, Ballereau S, Génisson Y, Ausseil F. Development of a CERT START Domain-Ceramide HTRF Binding Assay and Application to Pharmacological Studies and Screening. ACTA ACUST UNITED AC 2015; 20:779-87. [PMID: 25716975 DOI: 10.1177/1087057115573402] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Accepted: 01/09/2015] [Indexed: 11/16/2022]
Abstract
Sphingomyelin (SM) metabolism deregulation was recently associated with cell metastasis and chemoresistance, and several pharmacological strategies targeting SM metabolism have emerged. The ceramide (Cer) generated in the endoplasmic reticulum (ER) is transferred to the Golgi apparatus to be transformed into SM. CERamide Transfer (CERT) protein is responsible for the nonvesicular trafficking of Cer to Golgi. Blocking the CERT-mediated ER-to-Golgi Cer transfer is an interesting antioncogenic therapeutic approach. Here, we developed a protein-lipid interaction assay for the identification of new CERT-Cer interaction inhibitors. Frequently used for protein-protein interaction by enzymatic and analyte dosage assays, homogeneous time-resolved fluorescence technology was adapted for the first time to a lipid-protein binding assay. This test was developed for high-throughput screening, and a library of 672 molecules was screened. Seven hits were identified, and their inhibitory effect quantified by EC50 measurements showed binding inhibition three orders of magnitude more potent than that of HPA12, the unique known CERT antagonist to date. Each compound was tested on an independent test, confirming its high affinity and pharmacological potential.
Collapse
Affiliation(s)
| | - Céline Faux
- Unité de Service et de Recherche CNRS, Toulouse, France
| | - Cécile Santos
- LSPCMIB, CNRS-Université Paul Sabatier-Toulouse III, Toulouse, France
| | | | - Yves Génisson
- LSPCMIB, CNRS-Université Paul Sabatier-Toulouse III, Toulouse, France
| | | |
Collapse
|
4
|
Paganetti P, Weiss A, Trapp M, Hammerl I, Bleckmann D, Bodner RA, Coven-Easter S, Housman DE, Parker CN. Development of a method for the high-throughput quantification of cellular proteins. Chembiochem 2009; 10:1678-88. [PMID: 19492395 DOI: 10.1002/cbic.200900131] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The quantification of cellular proteins is essential for the study of many different biological processes. This study describes an assay for the detection of the intracellular mutant huntingtin, the causative agent of Huntington's disease, with a method that may be generally applicable to other cellular proteins. A small recombinant protein tag that is recognized by a pair of readily available, high-affinity monoclonal antibodies was designed. This tag was then added to an inducible fragment of the mutant huntingtin protein by genetic engineering. We show that it is possible to use time-resolved FRET to detect low intracellular levels of huntingtin by a simple lysis and detection procedure. This assay was then adapted into a homogeneous, miniaturized format suitable for screening in 1536-well plates. The use of time-resolved FRET also permits the assay to be multiplexed with a standard readout of cell toxicity, thus allowing the identification of conditions causing reduction of protein levels simply due to cytotoxicity. The screening results demonstrated that the assay is able to identify compounds that modulate the levels of huntingtin both positively and negatively and that represent valuable starting points for drug discovery programs.
Collapse
Affiliation(s)
- Paolo Paganetti
- Novartis Institutes for Biomedical Research Basel, Novartis Pharma AG, Basel, Switzerland.
| | | | | | | | | | | | | | | | | |
Collapse
|